Locally Advanced Pancreatic Cancer

Oncology
2
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

RenovoRx
RenovoRxMOUNTAIN VIEW, CA
1 program
1
GemcitabinePhase 31 trial
Active Trials
NCT03257033RecruitingEst. Sep 2026
OncoSil Medical
OncoSil MedicalAustralia - Macquarie Park
1 program
1
FOLFIRINOX chemotherapyPhase 21 trial
Active Trials
NCT05466799Active Not RecruitingEst. Jul 2027
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Carbon Ion RadiotherapyN/A1 trial
Active Trials
NCT01795274Withdrawn0

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
RenovoRxGemcitabine
OncoSil MedicalFOLFIRINOX chemotherapy

Clinical Trials (3)

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Start: Mar 2018Est. completion: Sep 2026
Phase 3Recruiting
NCT05466799OncoSil MedicalFOLFIRINOX chemotherapy

FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

Start: Apr 2023Est. completion: Jul 2027
Phase 2Active Not Recruiting
NCT01795274Heidelberg PharmaCarbon Ion Radiotherapy

Phase I Study Evaluating the Treatment of Patients With Locally Advanced Pancreatic Cancer With Carbon Ion Radiotherapy: The PHOENIX-01 Trial

0
N/AWithdrawn

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials
4 companies competing in this space